General Information of Drug (ID: DM7QGSX)

Drug Name
KW-2450 Drug Info
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Discontinued in Phase 1/2 [1]
Cross-matching ID
PubChem CID
56847547
CAS Number
CAS 1360433-93-7
TTD Drug ID
DM7QGSX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Teprotumumab DM4L59B Graves disease 5A02.0 Approved [3]
Mecasermin DM1O3BY Growth failure LD2F.1Y Approved [4]
Somatomedin-1 DMZ9FAO Hormone deficiency 5A61.1 Approved [5]
OSI-906 DMHKZLF Solid tumour/cancer 2A00-2F9Z Phase 3 [6]
Rinfabate DML9FD4 Solid tumour/cancer 2A00-2F9Z Phase 2/3 [7]
MM-141 DM2RJ4D Pancreatic cancer 2C10 Phase 2 [8]
TT-100 DMZE6Y9 Non-small-cell lung cancer 2C25.Y Phase 2 [9]
AMG 479 DM0DRAZ Breast cancer 2C60-2C65 Phase 2 [10]
VPI-2690B DMUQZT4 Diabetic nephropathy GB61.Z Phase 2 [11]
AXL-1717 DMTQ1Y3 Solid tumour/cancer 2A00-2F9Z Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Insulin receptor (INSR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meglitinides DM1OFHN Type-2 diabetes 5A11 Approved [13]
Human neutral insulin DMA5OBU Diabetic complication 5A2Y Approved [14]
Insulin Lyspro recombinant DM5XHVR Diabetic complication 5A2Y Approved [14]
Insulin, porcine DMO95XI Diabetic complication 5A2Y Approved [15]
Insulin recombinant DMYVP5G Diabetic complication 5A2Y Approved [14]
Metformin arginine-hemisuccinimide DMTPAM3 Type-2 diabetes 5A11 Approved [16]
Insulin-lispro DM4O90W Diabetic complication 5A2Y Approved [17]
Insulin-glulisine DMQI0FU Diabetic complication 5A2Y Approved [18]
Ryzodeq DMOFP18 Type-2 diabetes 5A11 Approved [19]
NN5401 DM0QV27 Diabetic complication 5A2Y Phase 3 [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin receptor (INSR) TTCBFJO INSR_HUMAN Modulator [2]
Insulin-like growth factor I receptor (IGF1R) TTHRID2 IGF1R_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030562)
2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
5 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
6 Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5.
7 Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7.
8 MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
9 BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
10 Clinical pipeline report, company report or official report of Amgen (2009).
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7.
13 New drugs for type 2 diabetes mellitus: what is their place in therapy Drugs. 2008;68(15):2131-62.
14 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
15 Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9.
16 Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004 Jun 1;67(11):2081-91.
17 Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2.
18 Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57.
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).